Upgrade to SI Premium - Free Trial

UBS Reiterates Buy Rating on Summit Therapeutics plc (SMMT)

September 8, 2026 9:12 AM
UBS analyst David Dai reiterated a Buy rating and $33.00 price target on Summit Therapeutics plc (NASDAQ ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments